Compare VanEck Australian Floating Rate ETF (FLOT) vs Oscar Health Inc (OSCR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Australian Floating Rate ETF vs Oscar Health Inc — how do they compare? VanEck Australian Floating Rate ETF trades at $50.95 (market cap $11.24B), while Oscar Health Inc trades at $33.27 (market cap $10.22B). The key difference: VanEck Australian Floating Rate ETF and Oscar Health Inc are close in size by market cap, and Oscar Health Inc is trading nearer its 52-week high, VanEck Australian Floating Rate ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Australian Floating Rate ETF for 21 Days and Oscar Health Inc for 15 Days on average.
| FLOT | OSCR | |
|---|---|---|
Market Cap | $11.24B | $10.22B |
Volume | 1,872,962 | 4,123,394 |
Sector | Fixed Income | Health |
52-Week High | $51.07 | $33.81 |
52-Week Low | $50.72 | $10.85 |
Typical Hold Time | 21 Days | 15 Days |
Enterprise Value | — | $6.57B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLOT trades at $50.91 with minimal daily movement (-0.02%). Technical indicators show a bearish trend with moving averages signaling sell pressure, though oscillators remain neutral. Recent dividend distributions of $0.17-$0.18 highlight income generation. The ETF benefits from floating rate exposure amid Fed tightening cycles, though concentration risk in bank holdings (47% exposure) warrants attention.
Outlook remains tied to interest rate trajectory, with FLOT positioned to benefit from higher rates. Key risks include bank sector concentration and Fed policy shifts. The current technical weakness suggests cautious near-term momentum despite the floating rate advantage in rising rate environments.
OSCR trades at $33.05, up 0.43% today, with strong technical momentum indicated by bullish moving averages. The company shows impressive growth with Q1 and Q2 2026 EPS beats and projected 2026 revenue of $15.3B. Valuation metrics appear reasonable with P/S of 0.63 and EV/EBITDA of 7.79, while profitability metrics show significant improvement from 2025 losses to projected 2026 net income of $551M.
The outlook remains positive with analyst consensus at $34.00 target and Strong Buy ratings from Zacks. Key opportunities include ACA market share gains and margin expansion, while risks center on rising medical costs and execution of growth targets. The stock faces near-term resistance at $34 with RSI suggesting potential overbought conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About VanEck Australian Floating Rate ETF
FLOT provides exposure to a diversified portfolio of Australian dollar-denominated floating rate notes. It tracks the Bloomberg AusBond Credit FRN 0+ Yr Index, focusing on high-quality, investment-grade bonds from top Australian banks and financial institutions.
Read more on FLOT →About Oscar Health Inc
Oscar Health, Inc. is a health insurance company that utilizes a technology-driven approach to simplify the healthcare experience. The company offers individual, small-group, and Medicare Advantage plans, primarily through a platform that integrates technology, data, and design to provide members with a personalized, efficient healthcare journey. Oscar aims to lower costs and improve engagement by focusing on consumer-centricity and modernizing the traditional health insurance model.
Read more on OSCR →
